AstraZeneca PLC (AZN)vsLiquidia Technologies Inc (LQDA)
AZN
AstraZeneca PLC
$168.10
+0.16%
HEALTHCARE · Cap: $257.57B
LQDA
Liquidia Technologies Inc
$68.64
+3.33%
HEALTHCARE · Cap: $5.95B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13509% more annual revenue ($61.37B vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs 17.0%. AZN trades at a lower P/E of 24.9x. LQDA earns a higher WallStSmart Score of 60/100 (C).
AZN
Buy60
out of 100
Grade: C+
LQDA
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$168.10
$27.71 discount
Intrinsic value data unavailable for LQDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 31.3x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, P/E Ratio, Price/Book. A P/E of 47.5x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while LQDA is a growth play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.54 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 60/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?